The clinical findings and laboratory tests included a metabolic profile and biosafety, which will be made at baseline. Body weight, body fat, body mass index and blood pressure were performed during the initial visit, likewise, interstitial glucose concentrations by ambulatory continuous glucose monitoring system (Guardian®, Medtronic MiniMed, Northridge), through which the mean amplitude of glucose excursions [MAGE] and area under the curve of glucose were calculated, which served to assess the glycemic variability. Adverse events and adherence to treatment were documented. Statistical analysis: Mann-Whitney U test, Wilcoxon, Chi2, Fisher exact test. It is considered with significance at p <0.05.